The targeted delivery of radionuclides to tumours holds great promise for diagnosis and
treatment of malignant neoplasms. The development of scaffold proteins has significantly …

Targeting of human epidermal growth factor type 2 (HER2) using monoclonal antibodies,
antibody-drug conjugates and tyrosine kinase inhibitors extends survival of patients with …

Monoclonal antibodies are the classical basis for targeted therapy, but the development of
alternative binding proteins has made it possible to use non-immunoglobulin proteins as …

The human epidermal growth factor receptor family (EGFR-family, other designations: HER
family, RTK Class I) is strongly linked to oncogenic transformation. Its members are …

Affibodies and designed ankyrin repeat proteins (DARPins) are synthetic proteins originally
derived from the Staphylococcus aureus virulence factor protein A and the human ankyrin …

Natural products provide a bountiful supply of pharmacologically relevant precursors for the
development of various drug-related molecules, including radiopharmaceuticals. However …

Phenothiazines (PTZs) are a group of compounds characterized by the presence of the 10H-
dibenzo-[b, e]-1, 4-thiazine system. PTZs used in clinics as antipsychotic drugs with other …

Radionuclide-based imaging of molecular therapeutic targets might facilitate stratifying
patients for specific biotherapeutics. New type of imaging probes, based on designed …

Epithelial cell adhesion molecule (EpCAM) is overexpressed in 55%–75% of ovarian
carcinomas (OC). EpCAM might be used as a target for a treatment of disseminated OC …

Background Designed ankyrin repeat proteins (DARPins) are small engineered scaffold
proteins (14–18 kDa) that demonstrated promising tumor-targeting properties in preclinical …